Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
NCT04204941 · Epizyme, Inc. · PHASE1 · terminated · last registry update 2026-01-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns” | – | Registry record, Epizyme, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EZH2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: National Cancer Institute (NCI), Pembrolizumab + Tazemetostat Hydrobromide (NCT05353439)
- 2026-11-10Also stopped (terminated): National Cancer Institute (NCI), Pembrolizumab + Tazemetostat Hydrobromide (NCT05353439)
- 2026-10-28Results posted on the registry: Epizyme, Inc., Tazemetostat (NCT02875548)
- 2026-10-28Also stopped (terminated): Epizyme, Inc., Tazemetostat (NCT02875548)
- 2026-09-01Results posted on the registry: National Cancer Institute (NCI), Dabrafenib Mesylate + Tazemetostat Hydrobromide (NCT04557956)
- 2026-04-17Also stopped (terminated): University of Alabama at Birmingham, Tazemetostat (NCT05983965)
- 2026-04-16Also stopped (terminated): Epizyme, Inc., Tazemetostat (NCT04241835)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-04-02Also stopped (terminated): Weill Medical College of Cornell University, Venetoclax + Tazemetostat (NCT05618366)
- 2026-04-01Also stopped (withdrawn): Eric Jacobsen, MD, Tazemetostat + Doxorubicin (NCT06692452)
- 2026-03-17Also stopped (terminated): Prisma Health-Upstate, Tazemetostat (NCT05023655)
- 2026-03-10Results posted on the registry: Epizyme, Inc., Tazemetostat + Abiraterone/prednisone (NCT04179864)
- 2026-03-10Also stopped (terminated): Epizyme, Inc., Tazemetostat + Abiraterone/prednisone (NCT04179864)
- 2026-02-04Results posted on the registry: University of Florida, Tazemetostat (NCT04917042)
- 2026-01-30Also stopped (withdrawn): Epizyme, Inc., Tazverik (Tazemetostat) (NCT06068881)
- 2026-01-21Also stopped (suspended): City of Hope Medical Center, Epcoritamab + Tazemetostat (NCT06575686)
- 2025-03-11Results posted on the registry: Epizyme, Inc., Tazemetostat (NCT02601950)
- 2025-03-06Results posted on the registry: National Cancer Institute (NCI), Tazemetostat (NCT03348631)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision